Verseon is engaged in the development of novel drug candidates using physics and AI-driven precision engineering, focusing on treatments for major human diseases.

Verseon

Verseon | 1,360 followers on LinkedIn. Game-Changing Technology, 
Life-Changing Medicines | Verseon delivers pharmaceutical solutions using proprietary, computer-driven drug discovery platform technology. Through scientific advancements in physics- and chemistry-based modeling, Verseon’s gol is to address the cycle of slow and derivative pharmaceutical developments to create truly novel molecular entities. We innovate beyond the bounds of the known and design, test, and synthesize never-been-seen molecules that may soon become life-changing drugs.

Head of Machine Learning Applications at Verseon

Edward Ratner

Anirban Datta

Kevin Short

Small Molecule Drug Discovery • Translational Research • Clinical Development • Biotech R&D • Strategic Guidance • Managing People • Building Drug…

David Kita

We're exploring uncharted chemical space to find drugs that dramatically improve disease treatment. Newsweek just published an article describing how we combine our fundamental quantum physics advances and innovative AI to systematically create medical breakthroughs. We’re finding answers for major human diseases that have long stood as formidable challenges: first-in-class treatments to safely prevent strokes and heart attacks, diabetic end-organ damage, and more. #Verseon #AIinMedicine #DrugDiscovery #HealthcareInnovation #Newsweek #MedicalBreakthroughs #Pharmaceuticals ➡️ https://lnkd.in/gmzvjbCt

Verseon platform featured as THE drug discovery solution in just released Forbes article on the future of medicine: https://lnkd.in/g9DFZKbA The way this article lays out the challenges and solutions to finding the life-changing medicines of the future makes it a worthwhile read. #AI #Health #Medicine #Pharmaceuticals

At Verseon, we relentlessly pursue technological advancements in-house whenever other current tools are inadequate to the tasks at hand. Our team’s most recent peer-reviewed paper describes our novel technique to combine AI models that offers a 150% improvement over the current state-of-the-art method. https://lnkd.in/guajFfNe #AI #DrugDiscovery #ensembling #innovation #pharmaceuticals #Verseon

Verseon's CEO Adityo Prakash recently shared some thought-provoking observations about the future of biotechnology and its implications for humanity in an article appearing on Homeland Security Today. #biotechnology #HomelandSecurity #medicine #pharmaceuticals #Verseon

Verseon is proud to introduce VersAI™, the world's most accurate AI for handling the small, sparse datasets typical of most real-world scenarios. Lack of big data is a major problem in small-molecule drug discovery, so we continue to develop our own tools, which now show utility far outside drug discovery alone. One of the biggest challenges facing most companies using AI today is getting their hands on enough high-quality training data for their specific applications. For all such scenarios, VersAI™ shines. As our peer-reviewed results show, VersAI™ yields up to 35% more accurate predictions than current state-of-the-art Google AutoML on benchmark datasets. https://lnkd.in/gtsaTf98 #AI #BigData #DrugDiscovery #GoogleAutoML #pharmaceuticals #smalldata #VersAI #Verseon

Inside Precision Medicine: How Verseon’s new tech unlocks a seemingly infinite chemical space inaccessible to the rest of the pharmaceutical industry. https://lnkd.in/gzjkexpj #AI #breakthrough #DrugDiscovery #pharmaceuticals #Verseon

Next Big Future’s Brian Wang reflects on the failures of current drug-discovery AI and references Verseon's approach as the solution. https://lnkd.in/g8_APixj #AI #DrugDiscovery #NextBigFuture #pharmaceuticals #Verseon

Adityo Prakash

Verseon's CEO Adityo Prakash speaks with Dan Turchin on the “AI and the Future of Work” podcast. #health #disease #aging #AI #quantum #physics #populationgrowth #sustainability

Verseon CEO Adityo Prakash discusses the role of AI in drug discovery and healthcare with Health Connective host Michael Roberts. https://lnkd.in/gc9aBftx #AI #healthcare #pharmaceuticals #HealthConnective #Verseon

Verseon CEO Adityo Prakash: "AI will make healthcare delivery much more efficient. But a major factor that determines cost... is human greed. Unfortunately, AI can’t help us there." https://lnkd.in/gnCUEMcG #Verseon #ABC #AI #healthcare #pharmaceuticals

Metric
Company Name	Verseon
Symbol
MSH ID	COM:VERSEON
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	verseon.com
LinkedIn	verseon
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VERS

COM:VERSEON

Verseon

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue